CN101903028B - 与吉西他滨组合用于治疗胰腺癌的中等链长脂肪酸、盐类及三酸甘油酯 - Google Patents

与吉西他滨组合用于治疗胰腺癌的中等链长脂肪酸、盐类及三酸甘油酯 Download PDF

Info

Publication number
CN101903028B
CN101903028B CN2008801221273A CN200880122127A CN101903028B CN 101903028 B CN101903028 B CN 101903028B CN 2008801221273 A CN2008801221273 A CN 2008801221273A CN 200880122127 A CN200880122127 A CN 200880122127A CN 101903028 B CN101903028 B CN 101903028B
Authority
CN
China
Prior art keywords
gemcitabine
cancer
pancreatic cancer
combination
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801221273A
Other languages
English (en)
Chinese (zh)
Other versions
CN101903028A (zh
Inventor
L·加农
L·格瑞特
C·彭尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prometic Biosciences Inc
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of CN101903028A publication Critical patent/CN101903028A/zh
Application granted granted Critical
Publication of CN101903028B publication Critical patent/CN101903028B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2008801221273A 2007-12-19 2008-12-18 与吉西他滨组合用于治疗胰腺癌的中等链长脂肪酸、盐类及三酸甘油酯 Expired - Fee Related CN101903028B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US812907P 2007-12-19 2007-12-19
US61/008,129 2007-12-19
PCT/CA2008/002190 WO2009076761A1 (en) 2007-12-19 2008-12-18 Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer

Publications (2)

Publication Number Publication Date
CN101903028A CN101903028A (zh) 2010-12-01
CN101903028B true CN101903028B (zh) 2013-06-05

Family

ID=40795145

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801221273A Expired - Fee Related CN101903028B (zh) 2007-12-19 2008-12-18 与吉西他滨组合用于治疗胰腺癌的中等链长脂肪酸、盐类及三酸甘油酯

Country Status (15)

Country Link
US (1) US8946190B2 (https=)
EP (1) EP2231166B1 (https=)
JP (1) JP5473937B2 (https=)
KR (1) KR101603351B1 (https=)
CN (1) CN101903028B (https=)
AU (1) AU2008338204B2 (https=)
BR (1) BRPI0821395A2 (https=)
CA (1) CA2708679C (https=)
DK (1) DK2231166T3 (https=)
ES (1) ES2414617T3 (https=)
MX (1) MX2010006867A (https=)
NZ (1) NZ586249A (https=)
PT (1) PT2231166E (https=)
TW (1) TWI448290B (https=)
WO (1) WO2009076761A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2427416E (pt) 2009-05-04 2016-06-15 Prometic Pharma Smt Ltd Compostos aromáticos substituídos e seus usos farmacêuticos
MX365807B (es) * 2010-10-27 2019-06-14 Prometic Pharma Smt Ltd Compuestos y composiciones para el tratamiento del cáncer.
CN102617679B (zh) * 2012-03-13 2014-11-26 北京大学 一种共轭亚油酸与吉西他滨连接的前体药物制备方法及其应用
US9737538B2 (en) 2013-02-12 2017-08-22 Bend Research, Inc. Solid dispersions of low-water solubility actives
WO2014126969A1 (en) * 2013-02-12 2014-08-21 Bend Research, Inc. Solid dispersions of low-water solubility actives
WO2014132134A1 (en) 2013-02-28 2014-09-04 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
WO2015116782A1 (en) 2014-01-29 2015-08-06 Board Of Regents, The University Of Texas System Nucleobase analogue derivatives and their applications
MA53188A1 (fr) 2018-10-11 2021-12-31 Basf As Composés aromatiques et leurs utilisations pharmaceutiques

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1633286A (zh) * 2001-04-18 2005-06-29 普罗米蒂克生物科学公司 作为中性白细胞存活和激活因子的中链长度的脂肪酸、甘油酯和类似物
CN1753665A (zh) * 2003-02-07 2006-03-29 普罗米蒂克生物科学公司 作为红细胞生成刺激剂的中链长脂肪酸类、甘油酯类和类似物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010441A1 (en) * 1989-03-13 1990-09-20 Thornfeldt Carl R Treatment of skin diseases and tumors
US6340705B1 (en) * 1999-09-10 2002-01-22 Monsanto Technology, Llc Use of α-linolenic acid metabolites for treatment or prevention of cancer
AU2002329842B2 (en) * 2001-08-29 2006-09-14 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
US20060012880A1 (en) * 2002-05-02 2006-01-19 Law Benjamin P Optical device with refractive and diffractive properties
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1633286A (zh) * 2001-04-18 2005-06-29 普罗米蒂克生物科学公司 作为中性白细胞存活和激活因子的中链长度的脂肪酸、甘油酯和类似物
CN1753665A (zh) * 2003-02-07 2006-03-29 普罗米蒂克生物科学公司 作为红细胞生成刺激剂的中链长脂肪酸类、甘油酯类和类似物

Also Published As

Publication number Publication date
EP2231166A4 (en) 2012-02-22
EP2231166A1 (en) 2010-09-29
JP2011506492A (ja) 2011-03-03
CN101903028A (zh) 2010-12-01
BRPI0821395A2 (pt) 2015-06-16
KR20100101134A (ko) 2010-09-16
KR101603351B1 (ko) 2016-03-14
ES2414617T3 (es) 2013-07-22
MX2010006867A (es) 2010-08-31
AU2008338204B2 (en) 2015-03-05
PT2231166E (pt) 2013-06-17
AU2008338204A1 (en) 2009-06-25
TW200934494A (en) 2009-08-16
JP5473937B2 (ja) 2014-04-16
US8946190B2 (en) 2015-02-03
NZ586249A (en) 2012-05-25
CA2708679C (en) 2016-11-15
US20100273731A1 (en) 2010-10-28
WO2009076761A1 (en) 2009-06-25
CA2708679A1 (en) 2009-06-25
DK2231166T3 (da) 2013-06-24
TWI448290B (zh) 2014-08-11
HK1151244A1 (en) 2012-01-27
EP2231166B1 (en) 2013-03-20

Similar Documents

Publication Publication Date Title
CN101903028B (zh) 与吉西他滨组合用于治疗胰腺癌的中等链长脂肪酸、盐类及三酸甘油酯
Velázquez et al. Butyrate inhibits seeding and growth of colorectal metastases to the liver in mice
CN105283180A (zh) Pi3k抑制剂与微管去稳定剂的药物组合
CN112566628A (zh) 预防和治疗癌症的药物组合物，包括棉酚、苯乙双胍和抗癌剂
CN1296818A (zh) 用于含癌的恶性新生物的抗恶性肿瘤剂
EP2999465A1 (en) Specific cancer treatment regimens with ganetespib
CN111514140B (zh) 一种mek抑制剂联合雄激素受体拮抗剂在制备治疗肿瘤药物中的用途
Luo et al. Analgesic effect of different dosage of Flurbiprofen axetil in laparoscopic cholecystectomy in comparison with other analgesic drugs.
HK1151244B (en) Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer
US20070269531A1 (en) Non-Steroid Anti-Inflammatory Agents with Vitamins, Minerals, and Dietary Supplements for the Prevention and Treatment of Primary, Secondary and Tertiary Cancer
JP7450037B2 (ja) 脳転移を有する末期非小細胞肺がん患者を治療するための組み合わせ医薬品
Ogata et al. Long-term survival following treatment with antineoplastons for colon cancer with unresectable multiple liver metastases: report of a case
WO2020090698A1 (ja) 医薬組成物
Deshmukh Modulation of Intestinal Flora as an Emerging Therapeutic Approach for the Treatment of Colon Cancer
EP4378466A1 (en) Pharmaceutical composition and anti-tumor agent for tumors that have at least either impaired bap1 or pbrm1 function
CN116808052A (zh) D-甘露糖制备降解egfr蛋白药物的应用
CN106176757B (zh) 一种化合物与替吉奥联合在制备治疗增生性疾病中的药物中的用途
WO2008064596A1 (fr) Composition pharmaceutique comprenant la protéine p43 pour le traitement de l'adénocarcinome gastrique
Lu 3508 POSTER Hugl-1 mutation has a correlation with the hepatocellular carcinoma progression
CN116997340A (zh) 用于治疗胰腺癌的PI3K-δ抑制剂
CN115444938A (zh) cGAS抑制剂与化疗药物联合在制备治疗肺癌药物中的用途
CN110876803A (zh) 一种包含乳蛋白和油酸的药物组合物
HK40049617A (en) Pharmaceutical composition for preventing or treating cancer, comprising gossypol, phenformin, and anticancer agent
Norris DIPG-15. Polyamine Pathway Inhibition is a Potent Novel Therapeutic Strategy Against Diffuse Intrinsic Pontine Glioma
Yang et al. 269P Transarterial ethanol ablation combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1151244

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1151244

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160725

Address after: cambridge

Patentee after: PROMETIC BIOSCIENCES Inc.

Address before: Quebec

Patentee before: Prometic Biosciences Inc.

PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer

Effective date of registration: 20181016

Granted publication date: 20130605

Pledgee: Structured Alfa L.P.

Pledgor: PROMETIC BIOSCIENCES Inc.

Registration number: 2018990000969

PE01 Entry into force of the registration of the contract for pledge of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130605

CF01 Termination of patent right due to non-payment of annual fee